Promising preliminary Phase 2b (ASCEND) pancreatic cancer data (Cohort A) reported with Cohort B data anticipated in the coming monthsEnrollment ...
The stock experienced a severe reaction following the preliminary data announcement from cohort A of the Ascend trial, indicating potential market misinterpretation. Lisata Therapeutics Inc ...
Hosted on MSN1mon
Lisata falls after mid-stage data for anticancer agentLisata Therapeutics (NASDAQ ... Citing early data from Cohort A of its ongoing ASCEND study, which is designed to evaluate certepetide with standard-of-care chemotherapy in mPDAC, LSTA said ...
Lisata Therapeutics Inc (LSTA) advances its pipeline with promising trial results for certepatide, despite facing financial ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback